Nirsevimab significantly protected infants against RSV disease in Phase 3 trial.Sanofi recognized by S&P as one of the most sustainability-committed companies.Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris.Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates.Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma. Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency.Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |